Popular on Rezul
- Parade of Homes Winners Announced
- August Real Estate Co. Launches Company with Two Developments Underway
- Cap L Debuts at Number one on iTunes
- United Real Estate's Bullseye™ Integrated VideoFizz Technology Solution Drives 603% Growth in Consumer Video Traffic in Q3
- Five Colleges Selected as NACCE 2020 Pitch for the Trades Winners
- A Fresh, Bold Analysis of Black Female Leadership Serving as a Playbook for Successful and Sustained Corporate Diversity, Equity and Inclusion
- Thompson Realty Capital and Trez Capital Break Ground on New Apartment Community Outside Austin
- New Concept in Live Concert Streaming Helps Theater Venues Generate Needed Cash
- AUA sponsors free sickle cell screening program for newborns in Antigua
- Q3 2020 | Houston Office | Research and Forecast Report
Similar on Rezul
- ILoveLeasing.com® Spherexx CRM Gains Twenty-Four Companies in 2020
- Want to Buy Website Traffic? Here's What You Should Know
- Richmond, VA-Based Digital Forensic Firm Launches Remote Mobile Forensic Data Acquisition
- CEO Coaching International Sees Record Attendance at Make Big Happen® Connections Virtual Forum
- Syxsense Experiences Record-Breaking Growth As Millions of Remote Workers Create Cyber Security Demand
- CEO Coaching International Congratulates Yosemite Pathology Group on Recent Acquisition
- JUSTLAW tackles systemic access to justice problem
- Dolby Atmos Now Available for Wohler's iAM-12G-SDI
- Local "We Buy Houses" Company Details how Covid-19 is Affecting the Housing Market in NC
- Greeting Card Association Announces Virtual Line Up
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in STAAR Surgical Company of Class Action Lawsuit and Upcoming Deadline - STAA
Rezul News/10486772
NEW YORK, Oct. 17, 2020 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ: STAA) and certain of its officers. The class action, filed in United States District Court for the Central District of California, Southern Division, and docketed under 20-cv-01660, is on behalf of a class consisting of all persons other than Defendants who purchased or otherwise acquired STAAR Surgical Company securities between February 26, 2020, and August 10, 2020, inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder by the SEC, 17 C.F.R. § 240.10b-5.
If you are a shareholder who purchased STAAR securities during the class period, you have until October 19, 2020, to ask the Court to appoint you as Lead Plaintiff for the class. A copy of the Complaint can be obtained at www.pomerantzlaw.com. To discuss this action, contact Robert S. Willoughby at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
More on Rezul News
[Click here for information about joining the class action]
STARR designs, develops, manufactures, and sells implantable lenses for the eye and companion delivery systems used to deliver the lenses into the eye. STAAR's primary products are: (1) "implantable Collamer® lenses," or "ICLs," used in refractive surgery; and (2) intraocular lenses, or "IOLs," used in cataract surgery.
The Complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts to investors. Specifically, Defendants misrepresented and/or failed to disclose to investors that the Company was overstating and/or mischaracterizing: (1) its sales and growth in China; (2) its marketing spend; (3) its research and development expenses; and that as a result of the foregoing, (4) Defendants' public statements were materially false and misleading at all relevant times.
On August 5, 2020, after the markets closed, STAAR reported disappointing financial results, as detailed below. On this news, shares of STAAR common stock fell approximately 10%, down from the August 5, 2020 closing price of $61.81 to an August 6, 2020 close of $55.86.
On August 11, 2020, analyst J Capital Research published a report in which it wrote that "[w]e think that STAAR Surgical has overstated sales in China by at least one-third, or $21.6 mln. That would mean that all of the company's $14 mln in 2019 profit is fake." The report continued that "[f]ake sales [in China] come at 100% margins and therefore translate directly into profit. That means that the roughly $21.6 mln in overstated Chinese sales in 2019 represents 152% of total company profit. In other words, without the fraud that we believe pervades the China business, STAAR is losing money."
More on Rezul News
J Capital Research stated in reaching its conclusions, it "conduct[ed] over 75 interviews, visited company sites in China and Switzerland, and reviewed financial statements and other government documents for STAAR's distributors and customers in China. We will show that sales of STAAR's ICLs are dramatically overstated."
On this news, the stock continued its descent, closing at just $48.25 per share on August 11, 2020.
The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.
CONTACT:
Robert S. Willoughby
Pomerantz LLP
[email protected]
SOURCE Pomerantz LLP
Related Links
www.pomerantzlaw.com
If you are a shareholder who purchased STAAR securities during the class period, you have until October 19, 2020, to ask the Court to appoint you as Lead Plaintiff for the class. A copy of the Complaint can be obtained at www.pomerantzlaw.com. To discuss this action, contact Robert S. Willoughby at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
More on Rezul News
- CEO Coaching International Sees Record Attendance at Make Big Happen® Connections Virtual Forum
- CGI Targets New MF Markets in TX and Western US; Taps DiSimone to Help Lead $500 MM Investment Push
- Great Grandma Invents a New Concept in Bridges
- Mizner Country Club Earns Another Year On Distinguished Clubs List
- Insivia Re-launches SaaS Founder Show
[Click here for information about joining the class action]
STARR designs, develops, manufactures, and sells implantable lenses for the eye and companion delivery systems used to deliver the lenses into the eye. STAAR's primary products are: (1) "implantable Collamer® lenses," or "ICLs," used in refractive surgery; and (2) intraocular lenses, or "IOLs," used in cataract surgery.
The Complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts to investors. Specifically, Defendants misrepresented and/or failed to disclose to investors that the Company was overstating and/or mischaracterizing: (1) its sales and growth in China; (2) its marketing spend; (3) its research and development expenses; and that as a result of the foregoing, (4) Defendants' public statements were materially false and misleading at all relevant times.
On August 5, 2020, after the markets closed, STAAR reported disappointing financial results, as detailed below. On this news, shares of STAAR common stock fell approximately 10%, down from the August 5, 2020 closing price of $61.81 to an August 6, 2020 close of $55.86.
On August 11, 2020, analyst J Capital Research published a report in which it wrote that "[w]e think that STAAR Surgical has overstated sales in China by at least one-third, or $21.6 mln. That would mean that all of the company's $14 mln in 2019 profit is fake." The report continued that "[f]ake sales [in China] come at 100% margins and therefore translate directly into profit. That means that the roughly $21.6 mln in overstated Chinese sales in 2019 represents 152% of total company profit. In other words, without the fraud that we believe pervades the China business, STAAR is losing money."
More on Rezul News
- PrimeArray Systems is thrilled to offer the must-have NAS features of 2021
- Syxsense Experiences Record-Breaking Growth As Millions of Remote Workers Create Cyber Security Demand
- CEO Coaching International Congratulates Yosemite Pathology Group on Recent Acquisition
- Life and Times of Alex Esguerra, Now Officially on Paperback
- The Paddington Real Estate Agent Showing That Boutique is Better
J Capital Research stated in reaching its conclusions, it "conduct[ed] over 75 interviews, visited company sites in China and Switzerland, and reviewed financial statements and other government documents for STAAR's distributors and customers in China. We will show that sales of STAAR's ICLs are dramatically overstated."
On this news, the stock continued its descent, closing at just $48.25 per share on August 11, 2020.
The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.
CONTACT:
Robert S. Willoughby
Pomerantz LLP
[email protected]
SOURCE Pomerantz LLP
Related Links
www.pomerantzlaw.com
Filed Under: Business
0 Comments
Latest on Rezul News
- OpsVeda 9.0 focuses on agility and automation needs of enterprises in the post-Covid era
- A Comprehensive Discussion at Offshorecorptalk.com Reveals Anonymous Cryptocurrencies
- Entrinsik Dominates in BARC – BI & Analytics 2021 Survey
- Tryp Technologies Inc Launching Delivery Service, TripDelivers in Nashville, TN
- Americans Bombarded by 9.4 Billion Political Robocalls This Year, Says Nomorobo Report
- Kuester Management Group Details Considerations When Faced with an HOA Board Resignation
- Precision Wins US HHS HubZone Showcase #3 SPOTLIGHT
- Swee Ng Sold a Home Over Listing Price in Gilbert AZ 85295
- Project Manager at Raajipo Builds More Than Homes for Hexa Builders
- Marc Ganzi, CEO of Colony Capital, Announced as a Keynote at The Connected Virtual Tech Event November 16th 2020
- QLSM is 5 Years of Therapy In Just 3 Hours Science Backed
- Peter Schiff's Bank Service to Criminals as Per the Tax Probe Triggers Sizzling Reactions at OffshoreCorpTalk.com
- Alovéa Partners with National Health Share in CELL-A-BRATE Health Project
- Beauty at the Beast – The Headless Horseman Rides Again
- The All-New Advanced Textile Polyfiber Boot Sock
- MarketKeep Partners with Heather Hilliard Design
- Q3 2020 | Houston Industrial | Research & Forecast Report
- Financial Solutions Inc. Adds Timeshare Cancellation Services
- FocalPoint Welcomes Certified Business Coach Cheryl Jett
- All of the "Favorite Brands" - Scrubs 2020